Zacks Investment Research upgraded shares of Nu Skin Enterprises, Inc. (NYSE:NUS) from a hold rating to a buy rating in a report issued on Wednesday morning. Zacks Investment Research currently has $70.00 target price on the stock.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
NUS has been the topic of a number of other reports. ValuEngine raised shares of Nu Skin Enterprises from a hold rating to a buy rating in a report on Friday, June 2nd. Pivotal Research reissued a buy rating and issued a $80.00 price target (up from $65.00) on shares of Nu Skin Enterprises in a report on Thursday, June 22nd. Sidoti downgraded shares of Nu Skin Enterprises from a buy rating to a neutral rating and set a $59.00 price objective on the stock. in a report on Wednesday, April 26th. Bank of America Corporation upped their price objective on shares of Nu Skin Enterprises from $53.00 to $57.00 and gave the company an underperform rating in a report on Monday, July 10th. Finally, Deutsche Bank AG upped their price objective on shares of Nu Skin Enterprises from $63.00 to $66.00 and gave the company a buy rating in a report on Wednesday, June 21st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $62.25.
Shares of Nu Skin Enterprises (NUS) opened at 62.99 on Wednesday. Nu Skin Enterprises has a 52 week low of $46.35 and a 52 week high of $66.04. The firm has a market cap of $3.33 billion, a PE ratio of 20.91 and a beta of 1.31. The firm has a 50-day moving average of $58.20 and a 200-day moving average of $53.72.
Nu Skin Enterprises (NYSE:NUS) last issued its quarterly earnings results on Wednesday, May 3rd. The company reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.01. The company had revenue of $499.10 million for the quarter, compared to the consensus estimate of $493.65 million. Nu Skin Enterprises had a net margin of 7.48% and a return on equity of 23.45%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.42 EPS. On average, analysts expect that Nu Skin Enterprises will post $3.12 EPS for the current year.
In related news, General Counsel D Matthew Dorny sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $56.39, for a total value of $451,120.00. Following the transaction, the general counsel now directly owns 52,730 shares in the company, valued at $2,973,444.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 24,250 shares of company stock worth $1,436,770. 5.20% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of NUS. BlackRock Inc. boosted its position in Nu Skin Enterprises by 21,593.4% in the first quarter. BlackRock Inc. now owns 6,683,531 shares of the company’s stock valued at $371,201,000 after buying an additional 6,652,722 shares during the period. Schroder Investment Management Group boosted its position in Nu Skin Enterprises by 139.4% in the first quarter. Schroder Investment Management Group now owns 1,711,619 shares of the company’s stock valued at $94,687,000 after buying an additional 996,731 shares during the period. Vanguard Group Inc. boosted its position in Nu Skin Enterprises by 11.8% in the first quarter. Vanguard Group Inc. now owns 6,011,632 shares of the company’s stock valued at $333,887,000 after buying an additional 634,951 shares during the period. State Street Corp boosted its position in Nu Skin Enterprises by 76.7% in the first quarter. State Street Corp now owns 1,416,873 shares of the company’s stock valued at $78,695,000 after buying an additional 614,817 shares during the period. Finally, Norges Bank bought a new position in Nu Skin Enterprises during the fourth quarter valued at $27,260,000. Institutional investors own 85.51% of the company’s stock.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Nu Skin Enterprises Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nu Skin Enterprises Inc. and related companies.